Pharma Tech Outlook: Specials Magazine

Drug development is evolving—shifting from small-molecule drugs (under 500 molecular weight) to larger (above 1,000), more complex compounds—designed to interact with biological pathways more precisely. Therapeutics like peptides and GLP-1 receptor agonists offer enhanced efficacy and target specificity but bring formulation challenges due to their size, fragility and poor oral bioavailability. These complexities demand advanced delivery systems and specialized handling. As a vertically integrated contract development and manufacturing organization (CDMO), Laviana Pharma navigates this complexity. By emphasizing early-stage formulation testing, Laviana helps uncover potential stability and delivery issues early, reducing downstream risks and accelerating the path to clinical success. Its scientific rigor and integrated capabilities make it a vital partner for companies bringing next-generation therapeutics to market. Speed and proximity have become Laviana’s key advantages. It has a specialized formulation laboratory in the U.S. designed specifically for the early-phase development of high-molecular-weight drug candidates. Working locally with U.S. clients means faster decisions, real-time adjustments and shorter timelines. Over the past 20 years, Laviana has helped develop hundreds of candidates and contributed to the successful launch of more than 30 drugs. Some of its early-stage collaborations have led to biotech breakthroughs later acquired by major pharmaceutical firms, an indicator of Laviana’s quiet but critical role in drug development success stories. Starting as a small CRO, Laviana quickly moved on to establishing its own pilot plant. After the R&D and manufacturing sites moved to their new locations, the upgrades Laviana received provided an advantage in equipment and capacity. Not only is Laviana able to do hydrogenation up to 2000 L, but the new trending high potency capability has also been recently added to Laviana’s portfolio. With a manufacturing capacity of up to 6300L and a team of more than 100 scientists, Laviana serves some of the most reputable pharmaceutical companies in the world. “Our role is to make drug development faster,” says Wenting Chen, co-founder and CEO. “Having early-stage development capabilities close to home with our hybrid supply chain strategy proves vital during emergencies like the pandemic when global supply chains get severely disrupted.” This strategy balances the reliability of local collaboration with the efficiency of global infrastructure. Along with the U.S.-based formulation lab, Laviana brings the globally distributed R&D and manufacturing network to advance programs from early development through commercialization. In Cangzhou, China, Laviana manages GMP manufacturing and the scale-up of high-potency APIs, where attention to regulatory compliance and technical detail is non-negotiable. Across the country in Beijing, the process development team uses AI-assisted retrosynthesis not as a buzzword, but as a practical tool, reworking complex synthesis routes to improve yields and cut down production time. Laviana’s fully automated facility in China is at the core of this integration, designed to support projects from early-stage research to late-phase clinical trials and commercial readiness.